

		<b>Interventions:</b>	Behavioral: Compliance; Behavioral: Message sidedness
808	Recruiting	<a href="#">Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission</a>	
		<b>Conditions:</b>	Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
		<b>Interventions:</b>	Biological: basiliximab; Biological: WT1 126-134 peptide vaccine; Drug: Montanide ISA 51 VG; Drug: poly ICLC;
809	Completed	<a href="#">Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia</a>	
		<b>Conditions:</b>	Infection; Leukemia
		<b>Intervention:</b>	Biological: trivalent influenza vaccine
810	Unknown †	<a href="#">Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery</a>	
		<b>Condition:</b>	Melanoma (Skin)
		<b>Interventions:</b>	Biological: D1/3-MAGE-3-His fusion protein; Biological: SB-AS02B adjuvant; Biological: SB-AS15 adjuvant
811	Recruiting	<a href="#">Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females</a>	
		<b>Condition:</b>	Human Papillomavirus Infection
		<b>Interventions:</b>	Biological: GSK Biologicals' HPV vaccine 580299; Biological: Merck's Human Papillomavirus Quadrivalent (Types
812	Completed	<a href="#">Vaccine Therapy in Treating Patients With Melanoma</a>	
		<b>Condition:</b>	Melanoma (Skin)
		<b>Interventions:</b>	Biological: HPV 16 E7:12-20 peptide vaccine; Biological: gp100 antigen; Biological: incomplete Freund's adjuvant; Procedure: conventional surgery
813	Active, not recruiting	<a href="#">Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects</a>	
	Has	<b>Condition:</b>	Human Papillomavirus Infection
		<b>Interventions:</b>	Procedure: Blood sampling; Procedure: Cervico-vaginal secretion (CVS) samples
814	Terminated	<a href="#">A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach</a>	
		<b>Condition:</b>	Leukemia, Lymphocytic, Chronic
		<b>Intervention:</b>	Biological: CLL vaccine using DNA plasmid vector
815	Completed	<a href="#">Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma</a>	
		<b>Condition:</b>	Melanoma (Skin)
		<b>Intervention:</b>	Biological: recombinant vaccinia-B7.1 vaccine
816	Active, not recruiting	<a href="#">Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable</a>	
		<b>Condition:</b>	Breast Cancer
		<b>Intervention:</b>	Biological: Autologous, Lethally Irradiated Breast Cancer Cells
817	Active, not recruiting	<a href="#">Donor Lymphocyte Infusion for Myeloma</a>	
		<b>Condition:</b>	Myeloma
		<b>Interventions:</b>	Biological: KLH Vaccine; Biological: KLH-id Vaccine; Drug: GM-CSF; Procedure: Apheresis; Procedure: Donor
818	Completed	<a href="#">An Intervention Promoting HPV Vaccination in Safety-net Clinics</a>	
		<b>Condition:</b>	Human Papilloma Virus-Related Cervical Carcinoma
		<b>Interventions:</b>	Behavioral: HPV brochure, recall, reminders; Behavioral: General Adolescent Vaccine Brochure
819	Completed	<a href="#">Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age</a>	

	<b>Has</b>	<b>Condition:</b>	Papillomavirus Vaccines
		<b>Intervention:</b>	Biological: Cervarix™ (HPV-16/18 L1 VLP AS04)
820	<b>Unknown †</b>	<a href="#">Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men</a>	
		<b>Conditions:</b>	Anal Cancer; HIV Infections
		<b>Intervention:</b>	Biological: Gardasil
821	<b>Unknown †</b>	<a href="#">Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma</a>	
		<b>Condition:</b>	Lymphoma, Low-Grade
		<b>Intervention:</b>	Biological: Favld (Id-KLH) active immunotherapy
822	<b>Withdrawn</b>	<a href="#">Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia</a>	
		<b>Condition:</b>	Chronic Myeloid Leukemia
		<b>Intervention:</b>	Biological: Allogeneic tumor cell vaccine
823	<b>Recruiting</b>	<a href="#">Multiple Antigen-Engineered DC Vaccine for Melanoma</a>	
		<b>Condition:</b>	Melanoma
		<b>Interventions:</b>	Biological: DC Vaccine + IFN; Biological: AdVTMM2/DC Vaccination
824	<b>Withdrawn</b>	<a href="#">Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)</a>	
		<b>Conditions:</b>	Cervical Cancer; Condylomata Acuminata
		<b>Intervention:</b>	Biological: V502
825	<b>Active, not recruiting</b>	<a href="#">Provenge (TM) for the Treatment of Hormone Sensitive Prostate Cancer</a>	
		<b>Condition:</b>	Prostate Cancer
		<b>Interventions:</b>	Other: Placebo; Biological: Provenge
826	<b>Active, not recruiting</b>	<a href="#">Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191</a>	
		<b>Conditions:</b>	Cervical Neoplasia; HPV Infections
		<b>Intervention:</b>	
827	<b>Recruiting</b>	<a href="#">Evaluating the Effectiveness of the Quadrivalent Human Papillomavirus (HPV) Vaccine at Preventing Anal HPV Infection in HIV-Infected Men</a>	
		<b>Condition:</b>	HIV Infections
		<b>Interventions:</b>	Biological: Quadrivalent HPV Vaccine; Biological: Placebo Vaccine for Male Participants Only; Biological: Placebo Vaccine for Female Participants Only
828	<b>Withdrawn</b>	<a href="#">Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma</a>	
		<b>Condition:</b>	Melanoma (Skin)
		<b>Interventions:</b>	Biological: gp100:209-217(210M) peptide vaccine; Biological: gp100:280-288(288V) peptide vaccine; Biological:
829	<b>Unknown †</b>	<a href="#">Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma</a>	
		<b>Condition:</b>	Melanoma (Skin)
		<b>Interventions:</b>	Biological: aldesleukin; Biological: gp100 antigen; Biological: incomplete Freund's adjuvant; Biological: sargramostim; Biological: tetanus peptide melanoma vaccine; Biological: tyrosinase peptide
830	<b>Completed</b>	<a href="#">Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma</a>	
		<b>Condition:</b>	Melanoma (Skin)
		<b>Interventions:</b>	Biological: Melan-A VLP vaccine, IMP321 adjuvant; Biological: adoptive immunotherapy; Biological: therapeutic autologous lymphocytes; Drug: cyclophosphamide; Drug: fludarabine phosphate
831	<b>Completed</b>	<a href="#">Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma</a>	
		<b>Conditions:</b>	Intraocular Melanoma; Melanoma (Skin)
		<b>Interventions:</b>	Biological: ipilimumab; Biological: Tyrosinase/gp100/MART-1 Peptides

832	Active, not recruiting	<a href="#">Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer</a>
		<b>Condition:</b> Advanced Cancer.
833	Completed	<a href="#">Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma</a>
		<b>Condition:</b> Melanoma (Skin)
834	Unknown †	<a href="#">Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's</a>
		<b>Condition:</b> Lymphoma
835	Recruiting	<a href="#">A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study</a>
		<b>Condition:</b> Genital Human Papilloma Virus Infection
836	Active, not recruiting Has	<a href="#">Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.</a>
		<b>Condition:</b> Human Papillomavirus Infection
837	Completed	<a href="#">Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma</a>
		<b>Conditions:</b> Melanoma; Neoplasm Metastasis
838	Unknown †	<a href="#">Vaccine Therapy in Treating Patients With Metastatic Melanoma</a>
		<b>Condition:</b> Melanoma (Skin)
839	Recruiting	<a href="#">Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study</a>
		<b>Conditions:</b> Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
840	Unknown †	<a href="#">Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery</a>
		<b>Conditions:</b> Intraocular Melanoma; Melanoma (Skin)
841	Completed	<a href="#">Health Care Decisions for Female Adolescents: The Role of Mothers and Daughters in Decision Making</a>
		<b>Condition:</b> Cervical Cancer
842	Recruiting	<a href="#">Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells Administered to Patients With Brain Tumors</a>
		<b>Condition:</b> Brain Tumors
843	Unknown †	<a href="#">Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma</a>
		<b>Conditions:</b> Intraocular Melanoma; Melanoma (Skin)

		<b>Interventions:</b>	Biological: incomplete Freund's adjuvant; Biological: multi-epitope melanoma peptide vaccine; Biological: sargramostim
844	Active, not recruiting	<a href="#">A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated</a>	
		<b>Condition:</b>	Melanoma
		<b>Intervention:</b>	Biological: TriMix-DC
845	Completed	<a href="#">Modified Vaccinia Ankara (MVA) Vaccine Study</a>	
		<b>Conditions:</b>	Nasopharyngeal Neoplasms; Epstein-Barr Virus Infections
		<b>Intervention:</b>	Drug: MVA Vaccine
846	Completed	<a href="#">Study to Evaluate Safety and Biological Activity of TroVax® Vaccine Given in Conjunction With IL-2 to Treat Locally Advanced or Metastatic</a>	
		<b>Condition:</b>	Carcinoma, Renal Cell
		<b>Intervention:</b>	Biological: TroVax®
847	Recruiting	<a href="#">Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients</a>	
		<b>Condition:</b>	Melanoma
		<b>Intervention:</b>	Biological: Theravac
848	Unknown †	<a href="#">Vaccine Therapy in Treating Patients With Malignant Melanoma</a>	
		<b>Condition:</b>	Melanoma (Skin)
		<b>Intervention:</b>	Biological: polyvalent melanoma vaccine
849	Active, not recruiting	<a href="#">Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma</a>	
		<b>Condition:</b>	Melanoma (Skin)
		<b>Interventions:</b>	Biological: denileukin diftitox; Biological: recombinant CD40-ligand; Biological: therapeutic autologous dendritic
850	Completed	<a href="#">Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma</a>	
		<b>Condition:</b>	Melanoma (Skin)
		<b>Interventions:</b>	Biological: OVA BiP peptide; Biological: gp209-2M antigen; Biological: recombinant 70-kD heat-shock protein; Biological: tyrosinase peptide
851	Unknown †	<a href="#">Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome</a>	
		<b>Condition:</b>	Myelodysplastic Syndromes
		<b>Interventions:</b>	Biological: PR1 leukemia peptide vaccine; Biological: incomplete Freund's adjuvant; Biological: sargramostim
852	Suspended	<a href="#">Immunization With 8 Peptides Mixed With Adjuvant Montanide ISA 51 in HLA-A2 Patients With Metastatic Cutaneous Melanoma</a>	
		<b>Condition:</b>	Malignant Melanoma
		<b>Intervention:</b>	Biological: 8 HLA-A2 restricted peptides and Montanide ISA-51
853	Recruiting	<a href="#">PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine</a>	
		<b>Condition:</b>	Renal Cell Carcinoma
		<b>Interventions:</b>	Drug: CT-011; Biological: DC/RCC fusion vaccine
854	Unknown †	<a href="#">Vaccine Therapy for Patients With Stage III Melanoma</a>	
		<b>Condition:</b>	Malignant Melanoma
		<b>Intervention:</b>	Biological: CancerVax vaccine (CANVAXIN)
855	Unknown †	<a href="#">Vaccine Therapy for Patients With Stage IV Melanoma</a>	
		<b>Condition:</b>	Malignant Melanoma
		<b>Intervention:</b>	Biological: CancerVax vaccine (CANVAXIN)
856	Active, not	<a href="#">Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas</a>	

	recruiting	<b>Condition:</b> Malignant Glioma
		<b>Interventions:</b> Biological: Dendritic vaccine pulsed with multiple peptides; Biological: The first booster vaccine phase.;
857	Completed	<a href="#">Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma</a>
		<b>Conditions:</b> Intraocular Melanoma; Melanoma (Skin)
		<b>Interventions:</b> Biological: gp100 antigen; Biological: incomplete Freund's adjuvant; Biological: ipilimumab
858	Active, not recruiting	<a href="#">Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine</a>
		<b>Condition:</b> Melanoma
		<b>Interventions:</b> Drug: Pegylated Interferon-Alfa 2b (PEG Intron); Drug: GP-100 Peptide Vaccine
859	Active, not recruiting	<a href="#">A Phase I/II Study Of Immunization With Lymphotoxin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells</a>
		<b>Condition:</b> Neuroblastoma
		<b>Intervention:</b> Biological: SJNB-JF-IL2 and SJNB-JF-Lptn cells and SKNLP Unmodified Neuroblastoma Cell Lines
860	Recruiting	<a href="#">The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study</a>
		<b>Condition:</b> Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
		<b>Intervention:</b> Biological: GSK580299 (CervarixTM)
861	Recruiting	<a href="#">Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer</a>
		<b>Condition:</b> Recurrent Ovarian Cancer
		<b>Interventions:</b> Drug: Interferon Alfa-2b; Biological: p53 SLP
862	Completed	<a href="#">Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed</a>
		<b>Condition:</b> Colorectal Neoplasms
		<b>Intervention:</b> Biological: TroVax
863	Recruiting	<a href="#">Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization</a>
		<b>Condition:</b> Melanoma
		<b>Interventions:</b> Biological: Dendritic Cell Immunization; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: T Cells;
864	Completed	<a href="#">Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma</a>
		<b>Condition:</b> Melanoma (Skin)
		<b>Interventions:</b> Biological: monoclonal antibody 4B5 anti-idiotypic vaccine; Biological: sargramostim; Drug: alum adjuvant
865	Completed	<a href="#">Vaccine Therapy in Treating Patients With Metastatic Melanoma</a>
		<b>Condition:</b> Melanoma (Skin)
		<b>Interventions:</b> Biological: aldesleukin; Biological: fowlpox virus vaccine vector; Biological: vaccinia-tyrosinase vaccine
866	Active, not recruiting	<a href="#">Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma</a>
		<b>Condition:</b> Melanoma (Skin)
		<b>Interventions:</b> Biological: MART-1 antigen; Biological: IL-2; Biological: gp100 antigen; Biological: GM-CSF; Biological: MART-
867	Completed	<a href="#">Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma</a>
		<b>Condition:</b> Melanoma (Skin)
		<b>Interventions:</b> Biological: MART-1 antigen; Biological: recombinant MAGE-3.1 antigen; Biological: recombinant interleukin-12
868	Recruiting	<a href="#">Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant</a>
		<b>Condition:</b> Multiple Myeloma
		<b>Intervention:</b> Biological: PCV13

869	Completed	<a href="#">Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy</a>	
		<b>Condition:</b>	Lymphoma
		<b>Intervention:</b>	Biological: ipilimumab
870	Completed	<a href="#">Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With</a>	
		<b>Condition:</b>	Melanoma
		<b>Intervention:</b>	Biological: KLH conjugates with GD2L and GD3L
871	Recruiting	<a href="#">Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma</a>	
		<b>Condition:</b>	Melanoma
		<b>Interventions:</b>	Biological: melanoma GVAX; Drug: Cyclophosphamide
872	Completed	<a href="#">Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21</a>	
		<b>Condition:</b>	Prostate Cancer
		<b>Intervention:</b>	Biological: MUC-2-KLH
873	Completed	<a href="#">Vaccine Therapy in Treating Patients With Stage IV Melanoma</a>	
		<b>Condition:</b>	Melanoma (Skin)
		<b>Interventions:</b>	Biological: D1/3-MAGE-3-His fusion protein; Biological: SB-AS02B adjuvant
874	Unknown †	<a href="#">Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission</a>	
		<b>Condition:</b>	Leukemia
		<b>Interventions:</b>	Biological: PR1 leukemia peptide vaccine; Biological: sargramostim; Other: placebo
875	Completed Has	<a href="#">Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients</a>	
		<b>Condition:</b>	Leukemia
		<b>Interventions:</b>	Drug: Sargramostim (GM-CSF); Biological: Pneumococcal Vaccine
876	Completed	<a href="#">Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma</a>	
		<b>Condition:</b>	Lymphoma
		<b>Intervention:</b>	Biological: Trivalent Baculovirus-expressed Influenza HA vaccine
877	Terminated Has	<a href="#">PR1 Vaccination in Myelodysplastic Syndrome (MDS)</a>	
		<b>Conditions:</b>	Leukemia; Myelodysplastic Syndrome
		<b>Intervention:</b>	Biological: PR-1 vaccine
878	Unknown †	<a href="#">Vaccine Therapy in Treating Patients With Metastatic Melanoma</a>	
		<b>Condition:</b>	Melanoma (Skin)
		<b>Interventions:</b>	Biological: QS21; Biological: incomplete Freund's adjuvant; Biological: peptide 946 melanoma vaccine; Biological: peptide 946-tetanus peptide conjugate melanoma vaccine; Biological: tetanus peptide melanoma
879	Completed Has	<a href="#">Men's Beliefs About Associations Between HPV, Cancers, and HPV Vaccination</a>	
		<b>Condition:</b>	Anus Neoplasms
		<b>Intervention:</b>	
880	Completed	<a href="#">Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma</a>	
		<b>Condition:</b>	Melanoma (Skin)

		<b>Interventions:</b>	Biological: aldesleukin; Biological: fowlpox virus vaccine vector; Biological: gp100 antigen
881	Completed	<a href="#">Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating</a>	
		<b>Condition:</b>	Melanoma
		<b>Intervention:</b>	Biological: autologous tumor cells plus GM-CSF-in Adjuvant
882	Recruiting	<a href="#">Id-KLH Vaccine + T Cells</a>	
		<b>Condition:</b>	Multiple Myeloma
		<b>Intervention:</b>	Biological: CD3/CD28
883	Completed	<a href="#">Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells</a>	
		<b>Condition:</b>	Melanoma
		<b>Intervention:</b>	Biological: DC/Apo-Nec
884	Completed	<a href="#">AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer</a>	
		<b>Condition:</b>	Bladder Cancer
		<b>Interventions:</b>	Biological: BCG vaccine; Drug: valrubicin; Procedure: conventional surgery
885	Completed	<a href="#">BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer</a>	
		<b>Condition:</b>	Bladder Cancer
		<b>Interventions:</b>	Biological: BCG vaccine; Biological: recombinant interferon alfa
886	Recruiting	<a href="#">Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies</a>	
		<b>Condition:</b>	Vaccine
		<b>Intervention:</b>	
887	Completed	<a href="#">Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma</a>	
		<b>Conditions:</b>	Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
		<b>Interventions:</b>	Biological: aldesleukin; Biological: gp100 antigen; Drug: Montanide ISA 51 VG; Procedure: quality-of-life assessment; Other: questionnaire administration; Other: laboratory biomarker analysis
888	Completed	<a href="#">Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been</a>	
		<b>Condition:</b>	Colorectal Cancer
		<b>Interventions:</b>	Biological: BCG vaccine; Biological: biological therapy; Drug: fluorouracil; Drug: semustine; Drug: vincristine sulfate
889	Active, not recruiting	<a href="#">Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)</a>	
		<b>Condition:</b>	Leukemia
		<b>Interventions:</b>	Biological: Peptide Vaccine (PR1 Peptide); Drug: Peginterferon alfa-2b; Drug: Imatinib; Drug: GM-CSF
890	Completed	<a href="#">Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer</a>	
		<b>Condition:</b>	Lung Cancer
		<b>Interventions:</b>	Biological: BCG vaccine; Biological: monoclonal antibody BEC2
891	Active, not recruiting	<a href="#">Vaccination of High Risk Breast Cancer Patients</a>	
		<b>Condition:</b>	Stage IV Breast Cancer
		<b>Intervention:</b>	Biological: Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG
892	Unknown †	<a href="#">Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer</a>	
		<b>Condition:</b>	Bladder Cancer

893	Completed	<b>Interventions:</b>	Biological: BCG vaccine; Drug: mitomycin C; Radiation: radiation therapy
		<b>Condition:</b>	Bladder Cancer
		<b>Interventions:</b>	Biological: BCG vaccine; Drug: mitomycin C; Procedure: adjuvant therapy; Procedure: conventional surgery
894	Recruiting	<b>Interventions:</b>	<a href="#">Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer</a>
		<b>Condition:</b>	Prostatic Neoplasms
		<b>Interventions:</b>	Biological: mRNA transfected dendritic cell; Drug: Docetaxel
895	Terminated	<b>Interventions:</b>	<a href="#">BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer</a>
		<b>Condition:</b>	Bladder Cancer
		<b>Interventions:</b>	Biological: BCG vaccine; Drug: gefitinib; Procedure: quality-of-life assessment
896	Unknown †	<b>Interventions:</b>	<a href="#">Surgery and BCG in Treating Patients With Bladder Cancer</a>
		<b>Condition:</b>	Bladder Cancer
		<b>Intervention:</b>	Biological: BCG vaccine
897	Recruiting	<b>Interventions:</b>	<a href="#">Immunotherapy With Racotumomab in Advanced Lung Cancer</a>
		<b>Conditions:</b>	NSCLC; Lung Cancer, Non-small Cell
		<b>Interventions:</b>	Biological: Racotumomab; Other: Best Support Treatment
898	Recruiting	<b>Interventions:</b>	<a href="#">Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)</a>
		<b>Condition:</b>	Leukemia
		<b>Interventions:</b>	Drug: lenalidomide; Biological: bystander vaccine
899	Terminated	<b>Interventions:</b>	<a href="#">A Vaccine Study for High Risk Cancers</a>
		<b>Conditions:</b>	Neuroblastoma; Rhabdomyosarcoma; Osteogenic Sarcoma
		<b>Intervention:</b>	Biological: MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine
900	Active, not recruiting	<b>Interventions:</b>	<a href="#">Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary</a>
		<b>Conditions:</b>	Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
		<b>Intervention:</b>	Procedure: Tumor collection
901	Completed	<b>Interventions:</b>	<a href="#">Tumor Lysate Pulsed-Dendritic Cell Vaccines After High-Dose Chemotherapy for Non-Hodgkin's Lymphoma</a>
		<b>Condition:</b>	Lymphoma, Non-Hodgkin
		<b>Intervention:</b>	Biological: tumor-pulsed dendritic cells
902	Completed	<b>Interventions:</b>	<a href="#">Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma</a>
		<b>Conditions:</b>	Brain Stem Glioma; Glioblastoma
		<b>Intervention:</b>	Biological: Dendritic cell Vaccine
903	Active, not recruiting	<b>Interventions:</b>	<a href="#">Vaccine Therapy in Treating Patients Who Are Being Considered For a Solid Organ Transplant and Are at Risk For Post-Transplant</a>
		<b>Condition:</b>	Lymphoproliferative Disorder
		<b>Intervention:</b>	Biological: autologous Epstein-Barr virus-transformed B-lymphoblastoid cell vaccine
904	Completed	<b>Interventions:</b>	<a href="#">The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer</a>
		<b>Condition:</b>	Bladder Cancer
		<b>Interventions:</b>	Drug: Gemcitabine 2 g; Drug: BCG Vaccine
905	Terminated	<b>Interventions:</b>	<a href="#">Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer</a>



	<b>Has</b>	<b>Condition:</b>	Small Cell Lung Cancer
		<b>Intervention:</b>	Biological: Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes
906	Recruiting	<a href="#">Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission</a>	
		<b>Condition:</b>	Multiple Myeloma
		<b>Interventions:</b>	Drug: Lenalidomide; Biological: Allogeneic Myeloma Vaccine; Biological: Prevnar-13
907	Completed	<a href="#">Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy</a>	
		<b>Condition:</b>	Neuroblastoma
		<b>Intervention:</b>	Biological: autologous neuroblastoma vaccine
908	Active, not recruiting	<a href="#">Daclizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide</a>	
		<b>Condition:</b>	Malignant Neoplasms Brain
		<b>Interventions:</b>	Biological: RNA-loaded dendritic cell vaccine; Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes; Drug: basiliximab; Drug: imiquimod
909	Terminated	<a href="#">Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or</a>	
		<b>Condition:</b>	Melanoma
		<b>Intervention:</b>	Biological: Montanide ISA 51
910	Terminated	<a href="#">A Pilot Study Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer</a>	
		<b>Condition:</b>	Metastatic Pancreatic Cancer
		<b>Intervention:</b>	Drug: Ontak
911	Completed	<a href="#">Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus,</a>	
	<b>Has</b>	<b>Conditions:</b>	Neoplasms, Glandular and Epithelial; Diphtheria; Tetanus; Whooping Cough; Poliomyelitis
		<b>Interventions:</b>	Biological: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine
912	Recruiting	<a href="#">Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas</a>	
		<b>Conditions:</b>	Brain Cancer; Brain Stem Tumors; Pontine Tumors
		<b>Intervention:</b>	Biological: Rindopepimut
913	Completed	<a href="#">Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus,</a>	
	<b>Has</b>	<b>Conditions:</b>	Neoplasms, Glandular and Epithelial; Diphtheria; Tetanus; Whooping Cough; Meningitis
		<b>Interventions:</b>	Biological: Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine; Biological: Comparator: Menactra™ (Concomitant); Biological: Comparator: Adacel™ (Concomitant); Biological: Comparator: Menactra™ (Non-
914	Recruiting	<a href="#">A Phase I Study of Intralesional Bacillus Calmette-Guérin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic</a>	
		<b>Condition:</b>	Metastatic Melanoma
		<b>Interventions:</b>	Biological: Bacillus Calmette-Guérin (BCG) vaccine; Drug: Ipilimumab
915	Completed	<a href="#">Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection</a>	
	<b>Has</b>	<b>Conditions:</b>	Infection; Precancerous Condition
		<b>Intervention:</b>	Biological: Gardasil
916	Active, not recruiting	<a href="#">Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells</a>	
		<b>Conditions:</b>	Metastatic Melanoma; Absence of CNS Metastases

917	Completed Has	<b>Intervention:</b>	Biological: Proteasome siRNA and tumor antigen RNA-transfected dendritic cells
		<a href="#">Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America</a>	
		<b>Conditions:</b>	Human Papillomavirus (HPV) Infection; Papillomavirus Vaccines
918	Active, not recruiting	<b>Intervention:</b>	Biological: Cervarix™
		<a href="#">Vaccination Plus Ontak in Patients With Metastatic Melanoma</a>	
		<b>Condition:</b>	Melanoma
919	Active, not recruiting	<b>Interventions:</b>	Drug: 4-peptide melanoma vaccine; Drug: 4-peptide melanoma vaccine plus Ontak; Drug: ontak
		<a href="#">Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine</a>	
		<b>Condition:</b>	Melanoma
920	Recruiting	<b>Interventions:</b>	Drug: KLH; Peptides; Dendritic Cells; Drug: KLH, peptides plus Montanide
		<a href="#">Community Awareness, Resources and Education (CARE): Project 3</a>	
		<b>Condition:</b>	Uterine Cervical Cancer
921	Unknown †	<b>Intervention:</b>	
		<a href="#">Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma</a>	
		<b>Condition:</b>	Melanoma (Skin)
922	Completed	<b>Interventions:</b>	Biological: Detox-B adjuvant; Biological: recombinant interferon alfa
		<a href="#">Immunotherapy of Melanoma Patients</a>	
		<b>Condition:</b>	Melanoma
923	Completed	<b>Interventions:</b>	Biological: Melan-A analog peptide; Biological: FluMa peptide; Biological: Mage-A10 peptide; Biological: SB AS-
		<a href="#">Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma</a>	
		<b>Condition:</b>	Melanoma (Skin)
924	Completed	<b>Interventions:</b>	Biological: MART-1 antigen; Biological: gp100 antigen; Biological: incomplete Freund's adjuvant; Biological:
		<a href="#">Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia</a>	
		<b>Condition:</b>	Acute Myelogenous Leukemia
925	Completed	<b>Intervention:</b>	Biological: GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)
		<a href="#">External Beam Radiation With Intratumoral Injection Of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma</a>	
		<b>Condition:</b>	Soft Tissue Sarcoma
926	Withdrawn	<b>Interventions:</b>	Biological: Dendritic cell injections; Procedure: Radiation therapy; Procedure: Surgery for tumor removal
		<a href="#">High Dose Influenza in Immunosuppressed Subjects</a>	
		<b>Condition:</b>	Influenza
927	Completed	<b>Interventions:</b>	Biological: rHAO Trivalent Influenza Vaccine; Biological: TIV
		<a href="#">Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by</a>	
		<b>Condition:</b>	Melanoma (Skin)
928	Completed	<b>Intervention:</b>	Drug: resiquimod
		<a href="#">Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines</a>	
		<b>Conditions:</b>	Melanoma; Skin
929	Terminated	<b>Interventions:</b>	Biological: human tyrosinase; Biological: mouse tyrosinase
		<a href="#">Immunization With the MAGE-3A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma</a>	
		<b>Condition:</b>	Malignant Melanoma